Article

Aziz Nazha Discusses the Future of Treating Patients With MDS

Author(s):

Aziz Nazha

Aziz Nazha, Hematology and Medical Oncology Fellow, Cleveland Clinic, discusses the future of treating patients with myelodysplastic syndrome (MDS).

Aziz Nazha, Hematology and Medical Oncology Fellow, Cleveland Clinic, discusses the future of treating patients with myelodysplastic syndrome (MDS).

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Waldenstrom macroglobulinemia is often slow growing, with high survival but lower quality of life over time, explained researcher Alisha Kimble.
Image of woman.
Image of two doctors and text.
Combining JNJ-1900 with Keytruda may improve distant control of lung cancer, explained by Dr. Jared Weiss.
image of serzan.
Dr. Breelyn Wilky explains that personalized treatments are helping improve outcomes for patients with gastrointestinal stromal tumors.
Image of two doctors with text.
Image of doctors with text.
Treatment with zanzalintinib plus Opdivo and Opdualag is an option worth exploring in patients with previously untreated clear cell renal cell carcinoma
Image of two doctors and text.
Related Content
Image of Jane.
June 6th 2025

The Invisibility of Blood Cancers to Others

Jane Biehl Ph.D.
I describe what it is like to have an “invisible” cancer.
Jane Biehl is a 12-year survivor of a very rare form of blood cancer, known as myelodysplastic syndrome (MDS). Catch up on all of Jane’s blogs here!
June 2nd 2025

Cancer Survivors Look Forward, Not Backward

Jane Biehl Ph.D.
As a cancer survivor I explain the importance of looking forward to life.
Dr. Suresh S. Ramalingam explains that patients with stage 3 lung cancer who undergo chemotherapy and radiation may develop radiation pneumonitis.
May 7th 2025

Managing Lung Inflammation After Chemoradiation and Tagrisso

Dr. Suresh S. Ramalingam
Dr. Suresh S. Ramalingam explains that patients with stage 3 lung cancer who undergo chemotherapy and radiation may develop radiation pneumonitis.
Jane Biehl is a 12-year survivor of a very rare form of blood cancer, known as myelodysplastic syndrome (MDS). Catch up on all of Jane’s blogs here!
April 24th 2025

Taking Charge of My Care and Advocacy Following a Cancer Diagnosis

Jane Biehl Ph.D.
After a long battle with illness and seeking many specialists, I emphasize the need to self-advocate for ongoing care following my cancer diagnosis.
Illustration of blood cell.
April 16th 2025

Bexmarilimab Plus Vidaza Elicit Responses in Myelodysplastic Syndromes

Ryan Scott
Treatment with bexmarilimab and Vidaza elicited high overall response rates in both frontline and relapsed/refractory higher-risk myelodysplastic syndrome.
CURE spoke with Dr. Michael K. Wong and Dr. Diwakar Davar about the use of ctDNA for patients with melanoma, and where the field may be headed.
April 11th 2025

What Role May ctDNA Have in Melanoma Management?

Dr. Michael K. Wong
CURE spoke with Dr. Michael K. Wong and Dr. Diwakar Davar about the use of ctDNA for patients with melanoma, and where the field may be headed.